Iovance Biotherapeutics, Inc. · 1 month ago
Quality Assurance Specialist I, Raw Material Release. Sunday to Wednesday [Contract to Hire]
Philadelphia, PA
Contract
Onsite
Entry Level
2+ years expIovance Biotherapeutics is a company focused on cell and gene therapy, and they are seeking a Quality Assurance Specialist I to support the review of documentation and the release of raw materials. The role involves ensuring compliance with cGMPs, reviewing batch records, and addressing any identified issues in a timely manner.
BiotechnologyClinical TrialsHealth CareHealth DiagnosticsMedical
Responsibilities
Ensure compliance to cGMPs and facility procedures
Interface with functional groups, such as Manufacturing, Quality Control, and Document Control, to determine events (errors, deficiencies, discrepancies, deviations and other observations) and report to management
Review of documentation associated with Raw materials, components in support of manufacturing operations
Review batch records and related production documentation, ensuring resolution of all identified issues prior product disposition, as required
Review of deviations as assigned
Revision of documents as assigned
Work with internal functions to address all identified issues in a timely manner
Reports errors, deficiencies, discrepancies, and observations to management
Disposition incoming materials
Preparing supporting documentation for release of materials
Issuance of labels, as required
Support lot closure
Other projects as assigned
Qualification
Required
A Bachelor's Degree in Science, Engineering, or a related technical discipline with at least 2 years of experience in a regulated industry or an advanced degree without experience
Working knowledge of cGMP regulations
Strong administrative skills including use of Microsoft Word, Excel, and PowerPoint
Attention to detail
Preferred
Prior experience in cell and gene therapy
Knowledge of QMS systems is a plus
Company
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
501-1000 employees
H1B Sponsorship
Iovance Biotherapeutics, Inc. has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (12)
2024 (11)
2023 (7)
2022 (7)
2021 (2)
2020 (2)
Funding
Current Stage
Public CompanyTotal Funding
$1.58B2024-02-20Post Ipo Equity· $211M
2023-07-10Post Ipo Equity· $150M
2020-05-27Post Ipo Equity· $603.7M
Leadership Team
Jean-Marc Bellemin
Chief Financial Officer
Cheryl Aranda
Executive Assistant to Chief Medical Officer
Recent News
2025-12-29
2025-12-07
2025-11-11
Company data provided by crunchbase